These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
362 related articles for article (PubMed ID: 26028030)
1. Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer. Niu J; Xue A; Chi Y; Xue J; Wang W; Zhao Z; Fan M; Yang CH; Shao ZM; Pfeffer LM; Wu J; Wu ZH Oncogene; 2016 Mar; 35(10):1302-1313. PubMed ID: 26028030 [TBL] [Abstract][Full Text] [Related]
2. DNA damage induces NF-κB-dependent microRNA-21 up-regulation and promotes breast cancer cell invasion. Niu J; Shi Y; Tan G; Yang CH; Fan M; Pfeffer LM; Wu ZH J Biol Chem; 2012 Jun; 287(26):21783-95. PubMed ID: 22547075 [TBL] [Abstract][Full Text] [Related]
3. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression. Guo GC; Wang JX; Han ML; Zhang LP; Li L Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302 [TBL] [Abstract][Full Text] [Related]
4. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer. Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605 [TBL] [Abstract][Full Text] [Related]
5. miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer. Wang J; Song C; Tang H; Zhang C; Tang J; Li X; Chen B; Xie X Breast Cancer Res; 2017 Jun; 19(1):72. PubMed ID: 28629464 [TBL] [Abstract][Full Text] [Related]
6. MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast cancer via direct targeting of STMN1. Li Y; Liang Y; Sang Y; Song X; Zhang H; Liu Y; Jiang L; Yang Q Cell Death Dis; 2018 Jan; 9(1):14. PubMed ID: 29323124 [TBL] [Abstract][Full Text] [Related]
7. Integrin α5 down-regulation by miR-205 suppresses triple negative breast cancer stemness and metastasis by inhibiting the Src/Vav2/Rac1 pathway. Xiao Y; Li Y; Tao H; Humphries B; Li A; Jiang Y; Yang C; Luo R; Wang Z Cancer Lett; 2018 Oct; 433():199-209. PubMed ID: 29964204 [TBL] [Abstract][Full Text] [Related]
8. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448. Bamodu OA; Huang WC; Lee WH; Wu A; Wang LS; Hsiao M; Yeh CT; Chao TY BMC Cancer; 2016 Feb; 16():160. PubMed ID: 26917489 [TBL] [Abstract][Full Text] [Related]
9. Curcumol enhances the sensitivity of doxorubicin in triple-negative breast cancer via regulating the miR-181b-2-3p-ABCC3 axis. Zeng C; Fan D; Xu Y; Li X; Yuan J; Yang Q; Zhou X; Lu J; Zhang C; Han J; Gu J; Gao Y; Sun L; Wang S Biochem Pharmacol; 2020 Apr; 174():113795. PubMed ID: 31926937 [TBL] [Abstract][Full Text] [Related]
10. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer. Ouyang M; Li Y; Ye S; Ma J; Lu L; Lv W; Chang G; Li X; Li Q; Wang S; Wang W PLoS One; 2014; 9(5):e96228. PubMed ID: 24788655 [TBL] [Abstract][Full Text] [Related]
11. A novel long non-coding RNA linc-ZNF469-3 promotes lung metastasis through miR-574-5p-ZEB1 axis in triple negative breast cancer. Wang PS; Chou CH; Lin CH; Yao YC; Cheng HC; Li HY; Chuang YC; Yang CN; Ger LP; Chen YC; Lin FC; Shen TL; Hsiao M; Lu PJ Oncogene; 2018 Aug; 37(34):4662-4678. PubMed ID: 29755127 [TBL] [Abstract][Full Text] [Related]
12. Ginsenoside Rg3 promotes cytotoxicity of Paclitaxel through inhibiting NF-κB signaling and regulating Bax/Bcl-2 expression on triple-negative breast cancer. Yuan Z; Jiang H; Zhu X; Liu X; Li J Biomed Pharmacother; 2017 May; 89():227-232. PubMed ID: 28231544 [TBL] [Abstract][Full Text] [Related]
13. A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer. D'Amato NC; Rogers TJ; Gordon MA; Greene LI; Cochrane DR; Spoelstra NS; Nemkov TG; D'Alessandro A; Hansen KC; Richer JK Cancer Res; 2015 Nov; 75(21):4651-64. PubMed ID: 26363006 [TBL] [Abstract][Full Text] [Related]
14. MicroRNA-181a suppresses salivary adenoid cystic carcinoma metastasis by targeting MAPK-Snai2 pathway. He Q; Zhou X; Li S; Jin Y; Chen Z; Chen D; Cai Y; Liu Z; Zhao T; Wang A Biochim Biophys Acta; 2013 Nov; 1830(11):5258-66. PubMed ID: 23911747 [TBL] [Abstract][Full Text] [Related]
15. Survivin Inhibitors Mitigate Chemotherapeutic Resistance in Breast Cancer Cells by Suppressing Genotoxic Nuclear Factor- Wang W; Zhang B; Mani AM; Wu Z; Fan Y; Li W; Wu ZH J Pharmacol Exp Ther; 2018 Jul; 366(1):184-193. PubMed ID: 29735611 [TBL] [Abstract][Full Text] [Related]
16. MiR-148a functions to suppress metastasis and serves as a prognostic indicator in triple-negative breast cancer. Xu X; Zhang Y; Jasper J; Lykken E; Alexander PB; Markowitz GJ; McDonnell DP; Li QJ; Wang XF Oncotarget; 2016 Apr; 7(15):20381-94. PubMed ID: 26967387 [TBL] [Abstract][Full Text] [Related]
17. The function role of miR-181a in chemosensitivity to adriamycin by targeting Bcl-2 in low-invasive breast cancer cells. Zhu Y; Wu J; Li S; Ma R; Cao H; Ji M; Jing C; Tang J Cell Physiol Biochem; 2013; 32(5):1225-37. PubMed ID: 24335172 [TBL] [Abstract][Full Text] [Related]
18. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525 [TBL] [Abstract][Full Text] [Related]
19. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase. Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267 [TBL] [Abstract][Full Text] [Related]
20. PDSS1-Mediated Activation of CAMK2A-STAT3 Signaling Promotes Metastasis in Triple-Negative Breast Cancer. Yu TJ; Liu YY; Li XG; Lian B; Lu XX; Jin X; Shao ZM; Hu X; Di GH; Jiang YZ Cancer Res; 2021 Nov; 81(21):5491-5505. PubMed ID: 34408002 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]